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Functional pancreatic neuroendocrine tumours (PNETs) are mainly represented by insuli-
noma, which secrete insulin independent of glucose and cause hypoglycaemia. The major
genetic alterations in sporadic insulinomas are still unknown. Here we identify recurrent
somatic T372R mutations in YY1 by whole exome sequencing of 10 sporadic insulinomas.
Further screening in 103 additional insulinomas reveals this hotspot mutation in 30%
(34/113) of all tumours. T372R mutation alters the expression of YY1 target genes in
insulinomas. Clinically, the T372R mutation is associated with the later onset of tumours.
Genotyping of YY1, a target of mTOR inhibitors, may contribute to medical treatment of
insulinomas. Our findings highlight the importance of YY1 in pancreatic b-cells and may
provide therapeutic targets for PNETs.
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P
ancreatic neuroendocrine tumours (PNETs) are classified
into functional and non-functional tumours by hormone
secretion and clinical symptoms. The main type of
functional PNETs is insulinoma, which is derived from pancreatic
b-cells and constantly secretes insulin or proinsulin. Germline
mutations of MEN1 gene, which cause multiple endocrine
neoplasia type 1, can lead to the development of insulinoma1.
A recent study discovered frequent somatic mutations in MEN1,
DAXX/ATRX, TSC2 and PTEN genes in non-functional PNETs2.
However, the major genetic basis of functional PNETs and the
differences between functional and non-functional PNETs have
not been fully elucidated. Genetic investigation of insulinoma
may contribute to discovery of crucial genes controlling
tumorigenesis, proliferation and functions of pancreatic b-cells.
Moreover, previous studies have linked PNETs and diabetes
studies via several key genes and pathways in pancreatic b-cells.
The critical genes mutated in PNETs could be responsible for the
physiological regulation of pancreatic b-cells. For example,MEN1
regulates compensatory proliferation of b-cells and promotes
gestational diabetes in pregnant mice3. MEN1 could be targeted
for reversing hyperglycaemia in diabetic mice4. The regulation of
mammalian target of rapamycin (mTOR) pathway is crucial for
both PNETs and diabetes2,5–7. Therefore, the further genetic
explorations of insulinomas might provide potential therapeutic
targets for both PNETs and diabetes.
Here we identify recurrent T372R mutations in the transcrip-
tion factor YY1 (Yin Yang 1) by whole exome sequencing, and
validate this hotspot mutations in 30% sporadic insulinomas. Our
results may contribute to a new diagnostic classification and
medical therapy of PNETs.
Results
Recurrent YY1 T372R mutations in insulinomas. To determine
whether functional and non-functional PNETs share the similar
driver genes, we screened mutations of MEN1 and DAXX/ATRX
in 39 pairs of insulinoma and matched blood DNA. Compared
with non-functional PNETs with 43% MEN1 and 44% DAXX/
ATRX mutations, we only found one somatic mutation in MEN1
(2.5%) and one mutation in ATRX (2.5%). Global messenger
RNA profiling of insulinomas and non-functional PNETs also
showed distinctive expression patterns5. To explore the unique
driver genes in sporadic insulinoma, 10 pairs of tumour and
matched blood DNA excluding MEN1 and DAXX/ATRX
mutations were selected for whole exome sequencing in
discovery cohort (Supplementary Table S1). Sequencing was
performed on Hiseq2000 platform with NimbleGen 44M human
exome array. The average sequencing depth was 157-fold
(93X–200X), and 97.96% (97.50–98.60%) of the target regions
were covered at least 10-fold (Supplementary Table S2 and
Supplementary Fig. S1).
We identified 78 somatic mutations among the 10 tumours,
including 21 synonymous, 49 missense, 1 nonsense, 3 splice sites
and 4 frameshift (Supplementary Table S3), resulting in an average
of 8 (2–18) somatic mutations per tumour (Supplementary Table
S4). The most common substitution in these samples was the
C:G4T:A transition, similar to most cancer types (Supplementary
Table S5 and Supplementary Fig. S2). Strikingly, YY1 harboured
recurrent c.C1115G/p.T372R in three tumours, significantly higher
(P¼ 5.4E 10, Poisson probability function8) than the
background. In addition, we found somatic mutations in three
potential cancer-related genes, includingMLL3, H3F3A and LMO2
(Table 1). T372R mutation in YY1 has never been reported in
publically available databases (including 1,000 genomes and
dbSNP database).
We validated the T372R mutations in YY1, and then screened
this mutation in 103 additional insulinomas by Sanger sequencing
or pyrosequencing (Fig. 1a and Supplementary Fig. S3). The
screening cohort included matched tumour and blood DNA from
frozen samples, and formalin-fixed and paraffin-embedded (FFPE)
tumour tissues with partial-matched blood (Supplementary
Table S6). Our data showed that somatic c.C1115G/p.T372R
mutation in YY1 existed in 30% sporadic insulinomas, including
malignant (1/7) ones (Supplementary Table S7).
Clinical features of YY1 T372R mutation in insulinomas. To
study the clinical significance of YY1 mutations, all patients in the
cohort were divided into wild-type and T372R subgroups. The
appearance of insulinomas with wild-type YY1 was significantly
earlier than T372R subgroup in both male and female patients.
There was no significant difference in the percentage of YY1-
mutated tumours between benign and malignant insulinomas in
the cohort (Table 2 and Supplementary Table S8). Quantitative
analysis of Ki67 staining in insulinomas indicated similar pro-
liferative activity between YY1-mutated insulinoma cells and other
tumour cells (Supplementary Fig. S4). Interestingly, T372R muta-
tion in YY1 was also reported in one adrenal aldosterone-produ-
cing adenoma9. In other cancers, including breast cancer, prostate
cancer and colon cancer, overexpression of YY1 could be correlated
with tumorigenesis and poor prognosis10.
Functional T372R mutation in the zinc-finger domain of YY1.
YY1 is an important regulatory node in tumorigenesis, glucose
metabolic homoeostasis and epigenetic regulation processes11–15.
YY1 encodes a ubiquitously distributed transcription factor
belonging to the GLI-Kruppel class of zinc-finger proteins. The
highly conserved carboxy terminus C2H2-zinc-finger domains of
YY1 are responsible for DNA binding and transcriptional
repression. The repression domain of YY1 is mapped to the last
two and a half zinc fingers (amino acid 333–amino acid 397)12.
T372R mutation in YY1 locates in the third functional zinc-finger
domain, indicating that it may affect the repression functions of
YY1 (Fig. 1b,c). On the basis of co-crystal structure of protein–
DNA binding between YY1 zinc fingers and AAV P5 initiator16,
alterations in zinc-finger structure were predicted to locate on
DNA-contacting surface, suggesting effects of T372R on DNA
modifications and transcriptional regulation (Fig. 1d).
Table 1 | Recurrent YY1 T372R mutations and mutated potential tumour-related genes in insulinomas.
Gene Mutation type Position Allele
change
Amino
acid change
Case
numbers
Frequency (%) P-value Cancer Gene
Census
YY1 Missense Chr14: 100,743,807 C4G T372R 3/10 34/113 (30) 5.4E-10* No
MLL3 Missense Chr7: 151,874,400 A4G D2713G 1/10 NA NA Yes
H3F3A Missense Chr1: 226,252,135 A4G K28R 1/10 NA NA Yes
LMO2 Frameshift Chr11: 33,886,330 –4C P25fs 1/10 NA NA Yes
*Poisson probability function.
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Quantitative PCR analysis showed high YY1 expression in
insulinomas with wild-type and mutated YY1, as well as normal
human islets. The expression levels of wild-type and mutated YY1
were not significantly changed in insulinomas (Fig. 2a,b).
Immunofluorescence staining demonstrated that YY1 was mainly
expressed in the nucleus of insulinoma cells (Fig. 2c). Further,
in vitro 5-ethynyl-20-deoxyuridine (EdU) proliferation assays
indicate that overexpression of wild-type and mutated YY1
promotes proliferation of mouse insulinoma (MIN6) cells
(Fig. 2d). Taken together, our results suggested that T372R in
YY1 was a critical oncogenic mutation in insulinomas.
T372R mutation increases the transcriptional activity of YY1.
YY1 is a functional transcription factor in fundamental processes of
cancer and metabolism10,13,14. Previous studies have demonstrated
that YY1 is a common target of mTORC1. Inhibition of
mTOR results in decreased mitochondrial function and insulin/
insulin-like growth factor signalling by controlling YY1 activity in
skeletal muscle13,14. mTOR inhibition can decrease the
mitochondrial gene expression through direct modulation of YY1
activity, whereas overexpression of YY1 increases the expression of
mitochondrial genes13. To explore T372R mutation-induced
functional alterations of YY1, we examined the expression of a
few YY1 target genes in insulinomas. Our data showed significantly
increased expression of mitochondrial gene IDH3A and UCP2 in
YY1-mutated tumours. In addition, the expression of COL1A1
gene, which is positively regulated by YY1 (ref. 17), was
significantly upregulated in YY1-mutated tumours (Fig. 3). These
results suggested that T372R mutation could enhance the
transcriptional activity of YY1.
Discussion
YY1 regulates the mitochondrial function and insulin/insulin-like
growth factor signalling, which is crucial for pancreatic
b-cell survival and insulin secretion13,14,18,19. Our data indicate
that T372R mutation enhances the transcriptional activity of YY1.
Overexpression of mutated and wild-type YY1 promotes
proliferation of MIN6 cells. T372R mutation in YY1 and
overexpression of wild-type YY1 might have similar effects. These
studies have shed light on the importance of YY1 in energy
metabolism. The precise functions of YY1 in pancreatic b-cells could
be investigated in transgenic mouse models and human islets in the
future. The comprehensive understanding of physiological and
pathological functions of YY1 in b-cells might provide potential
therapeutic targets for diabetes.
Recently, the medical therapy of insulinoma and PNETs
has been investigated in a series of clinical studies20,21.
Everolimus (RAD001), an oral mTOR inhibitor, substantially
improves glycaemic control and reduces the tumour size in
patients with insulinoma20. Phase 2 and 3 clinical trials
demonstrated that Everolimus could prolong progression-free
survival in patients with advanced PNETs21. However,
the molecular mechanisms underlying these significant
TACACACGC CG
Blood Tumour
Blood
A G C A C G A G C A C G
Tumour
YY1 g.chr14:100743807C>G p.T372R
INS31
TA A AC CGC
Human
Mouse
Rat
Bovine
Chicken
Frog
Zebrafish
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQ
T372
Mammal conservation
T372R
Activation Repression Repression
YY1 protein
YY1 exons
DNA
C2H2 zinc-finger domain
T372R
R
EP
O
G
K Zn Zn Zn ZnHI
S
AC
ID
IC
AC
ID
IC
1                                                                                                   414
Figure 1 | Hotspot T372R mutations in YY1. (a) Validation of T372R
mutation by Sanger sequencing and pyrosequencing. (b) Human YY1
protein and exons. Domains and motifs responsible for transcriptional
regulation are indicated. Acidic, 11 consecutive acidic amino acids; His,
histidine-rich domain; GK, glycine–lysine-rich domain; REPO, recruitment of
polycomb domain; Zn, zinc-finger domain. Recurrent T372R mutations
locate in the third zinc finger. (c) Conservation of T372 in zinc-finger
domain. (d) Location of T372R mutation on crystal structure of C2H2-zinc-
finger domain in YY1.
Table 2 | T372R mutation in YY1 is associated with late
onset of insulinomas.
Wild type
(n¼ 79)
T372R (n¼ 34) P-value
Mean age at operation
(range in years)
46 (7–90) 56 (36–81) 0.00027*
Male 42 (7–90) 53 (44–62) 0.024*
Female 48 (22–74) 58 (36–81) 0.0043*
Gender: number (%)
Male 27 (75%) 9 (25%) 0.13w
Female 52 (68%) 25 (32%)
Pathological types: number (%)
Benign insulinoma 73 (69%) 33 (31%) 0.24w
Malignant insulinoma 6 (86%) 1 (14%)
*T-test.
wFisher’s exact test.
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therapeutic effects are still unclear. Interestingly, our results
revealed a potentially activating YY1 mutation in 30%
insulinomas, which might be treated with drugs targeting the
activity of YY1. Consistently, the mTOR inhibitors can control
and modify the transcriptional activity of YY1. Therefore, YY1
genotyping may contribute to diagnostic classification of
insulinomas and improve mTOR inhibitors’ therapy in the
future.
Collectively, our study reveals the YY1 mutation hotspot
T372R as an oncogenic mutation in 30% sporadic insulinomas.
These findings may provide new diagnostic and therapeutic
approaches for PNETs.
Methods
Clinical samples. Insulinomas were diagnosed by clinical hypoglycaemia symp-
toms, blood insulin and glucose levels (prolonged oral glucose tolerance test),
computed tomography/positron emission tomography-computed tomography
imaging of patients and pathological diagnosis of surgical removal tumour.
Genomic DNA was obtained from matched frozen insulinoma tumour and blood
samples, and FFPE insulinoma tissues with partial-matched blood in the endo-
crine-related tumour bank of Shanghai Key Laboratory for Endocrine Tumors.
Only matched frozen samples were used in the discovery cohort. DNA was pre-
pared with QIAGEN DNeasy Blood & Tissue Kit and QIAamp DNA FFPE Tissue
Kit. Normal human pancreatic islets were isolated from the donor pancreas for
transplantation. Normal human islets of Langerhans used in this study were iso-
lated according to the Edmonton protocol. Total RNA was prepared with QIAGEN
miRNeasy mini kit. Informed consent was obtained from all study participants. All
the protocols were approved by the Rui-jin Hospital Ethics Committee, Shanghai
Jiao Tong University School of Medicine.
Exome sequencing. The qualified genomic DNA from tumour and matched
peripheral blood from 10 insulinomas were fragmented by Covaris technology with
resultant library fragments 200–300 bp, and then adapters were ligated to both ends
of the fragments. Extracted DNA was then amplified by ligation-mediated PCR,
purified and hybridized to the NimbleGenEZ 44M human exome array for
enrichment, non-hybridized fragments were then washed out. Both non-captured
and captured ligation-mediated PCR products were subjected to quantitative PCR
to estimate the magnitude of enrichment. Each captured library was then loaded on
Hiseq2000 platform, and we performed high-throughput sequencing for each
captured library independently to ensure that each sample meet the desired average
fold-coverage. Raw image files were processed by Illumina base calling Software 1.7
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Figure 2 | Functional YY1 T372R mutations in insulinomas. (a) Quantitative reverse transcriptase (qRT)–PCR analysis of WT and T372R-mutated
YY1 expression in insulinomas. Original Ct values were normalized to housekeeping gene GAPDH (WT group, n¼8; T372R group, n¼ 5). (b) qRT–PCR
analysis of WT and T372R-mutated YY1 expression in normal human islets and insulinomas. Original Ct values were normalized to housekeeping
gene GAPDH (T372R group, n¼ 5; control group, n¼ 3). All of samples are benign insulinomas. Data represent mean±s.d. (c) Insulinoma sections were
stained with YY1 antibody (red) and insulin antibody (green). The data represents samples from six benign insulinomas in each group. Scale bars, 30mm.
(d) EdU staining and flow cytometric analysis. MIN6 cells were transfected with wild-type, T372R-mutated YY1 and vector control. The fold change of
EdU-positive cells were analysed. Data represent mean± SD, *Po0.05, Student’s t-test. The data shown represents three independent experiments.
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for base calling with default parameters and the sequences of each individual were
generated as 90 bp paired-end reads.
Reads mapping and variation detection. After removing reads containing
sequencing adapters and low-quality reads with more than five unknown bases,
high-quality reads were aligned to the NCBI human reference genome (hg19) using
Burrows–Wheeler Aligner (v0.5.9)22 with default parameters. Picard (v1.54)23 was
employed to mark duplicates and followed by Genome Analysis Toolkit (v1.0.6076,
GATK IndelRealigner)24 to improve alignment accuracy. Potential somatic single
nucleotide variants were predicted by Varscan2.2.5 (with parameters as http://
www.varscan.sourceforge.net/samtools (v0.1.18)25 mpileup –Q 0 and Varscan2.2.5 --
min-coverage 10 --min-coverage-normal 10 --min-coverage-tumour 10 --min-var-freq
0.1 --min-freq-for-hom 0.75 --min-avg-qual 0)26. Then we use our house pipeline to
identify somatic mutations, with major criteria as the following: adjacent somatic
mutation distance, mapping quality, base quality, allele frequency change between
tumour and adjacent normal, mutation should not be in gap-aligned reads, mutations
should not be significantly enriched within 5 bp of 50- or 30-ends of the reads and
mutations should not be in simple repeat region. Somatic InDels were predicted by
GATK SomaticIndelDetector with default parameters. Then we developed own
pipeline to get high confidence somatic indels, as following: combined normal and
tumour bam were reused to perform local realignment and germline indels were
filtered for high confidently indels, normal coverage and tumour coverage should be
Z10. High confidently somatic single nucleotide variants and InDels were annotated
using ANNOVAR (released 2011-10-02)27.
Validation of YY1 mutation by PCR and Sanger sequencing. PCR was per-
formed on Dual 96-well GeneAmp PCR System 9700 (Applied Biosystems), 20 ng
template DNA from each sample was used per reaction. The products were
sequenced by 3730xl DNA Analyzer (Applied Biosystems). All sequences were
analysed by the Sequencing Analysis Software Version 5.2 (Applied Biosystems).
Following primers were used: 50-CACCCAGGGCAGGAATG-30 for human
YY1-F1; 50-CCTGTCTCCGGTATGGA-30 for human YY1-R1.
Validation of mutations by pyrosequencing. Pyrosequencing was performed
on QIAGEN PyroMark Q96 ID system with PyroMark Q96 Vacuum Workstation
and PyroMark Gold Q96 Reagents, following the instructions in the user manual.
Following primers were used: 50-GGGAAACGCTTTTCACTGGAC-30 for
human YY1-F2; 50-TAGGGCCTGTCTCCGGTATG-30 for human YY1-R2 and
50-GGTATGGATTCGCACA-30 for sequencing.
Immunofluorescence staining. FFPE insulinoma tissues were deparaffinized
using standard techniques. Immunofluorescence staining were performed accord-
ing to the standard protocol. The following primary antibodies were used: poly-
clonal rabbit anti-YY1 antibody (1:100; ORIGENE, clone EPR4651) and polyclonal
guinea pig anti-insulin (1:400; Dako). The secondary antibodies for immuno-
fluorescence staining were purchased from Invitrogen and Dako. The images were
acquired using an Olympus microscopy system.
Real-time reverse transcription–PCR. Total RNA was extracted using QIAGEN
miRNeasy mini kit. For reverse transcription, 1 mg of total RNA was converted into
first-strand complementary DNA in a 20-ml reaction volume using a reverse
transcription kit following the manufacturer’s instruction. Quantitative real-time
PCR was then performed using a LightCycler 480 Real-Time PCR System (Roche
Applied Science). The comparative cycle threshold method was used to determine
the relative messenger RNA expression of human YY1 after normalization to
housekeeping gene GAPDH. The following primers were used:
50-CCTGGCATTGACCTCTCAGATCCCA-30 for human YY1-F3;
50-GGGCAAGCTATTGTTCTTGGAGCA-30 for human YY1-R3.
50-TTTGCCATGAAGTTCAATGCA-30 for human PGC1a-F,
50-AGCAGCCACAAAAAGGGAGAT-30 for human PGC1a-R.
50-GGTTCCTGGAACGTGGTGAT-30 for human Ucp2-F,
50-AGCCATGAGGGCTCGTTTC-30 for human Ucp2-R.
50-TGCTGCCAAAGCACCTATTCA-30 for human idh3a-F,
50-GTGACCGGCTGCTATTGGG-30 for human idh3a-R.
50-TCGCCGTCATGCTGGG-30 for human COX5a-F,
50-CAATAAATCCTTGGGGAAGCC-30 for human COX5a-R.
50-GGAGGGGATCAGTATATACA-30 for human CXCR4-F,
50-GAAGATGATGGAGTAGATGG-30 for human CXCR4-R.
50-CACCAATCACCTGCGGTACAGAA-30 for human Col1a1-F,
50-CAGATCACGTCATCGCACAAC-30 for human Col1a1-R.
Cell culture and transfection. Mouse MIN6 cell lines were kindly provided by Dr.
Xiao Wang (Shanghai Institute of Endocrine and Metabolic Diseases) and cultured
as described previously28,29. MIN6 cells were transfected with plasmids by
Lipofectamine 2000 (Invitrogen). Human full-length YY1 complementary DNA
was inserted in pCMV6 vector. T372R mutation was introduced into plasmids with
the QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instruction.
Flow cytometric analysis. MIN6 cells were transfected with wild-type, T372R-
mutated YY1 and vector controls for analysis. EdU staining was performed 24 h
after transfection. Cell proliferation assay was performed using EdU assay kit
(Click-iT EdU Flow Cytometry Assay Kit, Invitrogen); positive cells were analysed
by flow cytometry.
Computational modelling of T372R in YY1. The available protein crystal
structures of Human YY1 residues 293–414 and crystallization DNA complex
(PDB 1UBD) were identified as the template16. A three-dimensional model of the
YY1 C2H2-zinc-finger domains and DNA complex and T372R mutation was
generated using PyMOL software30.
Statistical analysis. Recurrent mutated YY1 was identified as a significant
mutated gene as described before8. Significant differences were analysed using
Student’s t-test or Fisher’s exact test. Error bars in graphs represent s.d. Differences
were considered significant if Po0.05.
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